US4568685A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-[(1H-1,2,4-Triazol-1-yl)alkyl]-arylamides
Assignee: Wyeth Holdings LLC
•
Filing: 1984-02-29
•
Granted: 1986-02-04
•
Expires: 2004-02-29
Abstract
Abstract N-[(1H-1,2,4-Triazol-l-yl)alkyl]arylamides which are inhibitors of thromboxane synthetase enzyme.
Inventors
- 👤 William B. Wright, Jr.
- 👤 Jeffery B. Press
- 👤 Andrew S. Tomcufcik
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 04:00
CPC Classifications
C; C07; C07D; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/54; C07D233/56; C07D249/00; C07D249/02; C07D249/08
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
99 words
A compound having the formula: ##STR8## wherein R 1 , R 2 and R 3 are each individually selected from the group consisting of hydrogen, halogen, trifluoromethyl, phenyl, straight or branched chain alkyl(C 1 -C 6 ), nitro, carboxy, cyano, amino, methylamino, dimethylamino, benzoyl, acetamido, alkoxy(C 1 -C 3 ), methylsulfonyl, methylthio and acetyl; R 1 and R 2 taken together are --(CH) 4 --; Q is --CH═CH--, cyclopropyl, ##STR9## where m is an integer 0-4; R 4 is hydrogen, alkyl(C 1 -C 4 ) or benzyl; and n is an integer 2-5, and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
99 words
A compound having the formula: ##STR8## wherein R 1 , R 2 and R 3 are each individually selected from the group consisting of hydrogen, halogen, trifluoromethyl, phenyl, straight or branched chain alkyl(C 1 -C 6 ), nitro, carboxy, cyano, amino, methylamino, dimethylamino, benzoyl, acetamido, alkoxy(C 1 -C 3 ), methylsulfonyl, methylthio and acetyl; R 1 and R 2 taken together are --(CH) 4 --; Q is --CH═CH--, cyclopropyl, ##STR9## where m is an integer 0-4; R 4 is hydrogen, alkyl(C 1 -C 4 ) or benzyl; and n is an integer 2-5, and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
7 words
The compound according to claim 1, 4-t-butyl-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 4
Dependent Claim
7 words
The compound according to claim 1, 4-iodo-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 5
Dependent Claim
7 words
The compound according to claim 1, 4-cyano-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 6
Dependent Claim
7 words
The compound according to claim 1, 3-fluoro-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 7
Dependent Claim
8 words
The compound according to claim 1, N-[4-(1H-1,2,4-triazol-1-yl)butyl]-1-naphthaleneacetamide, fumarate.
Claim 8
Dependent Claim
7 words
The compound according to claim 1, N-[3(3H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 9
Dependent Claim
7 words
The compound according to claim 1, 3,4-dichloro-N-[4-(1H-1,2,4-triazol-1-yl)butyl]benzamide.
Claim 10
Dependent Claim
7 words
The compound according to claim 1, 4-(1,1-dimethylethyl)-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 11
Dependent Claim
7 words
The compound according to claim 1, 3-chloro-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 12
Dependent Claim
7 words
The compound according to claim 1, 3-bromo-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 13
Dependent Claim
7 words
The compound according to claim 1, 4(dimethylamino)-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 14
Dependent Claim
7 words
The compound according to claim 1, 4-(methylsulfonyl)-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 15
Dependent Claim
7 words
The compound according to claim 1, 3,4,5-trimethoxy-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 16
Dependent Claim
7 words
The compound according to claim 1, 4-fluoro-N-[3-(1H-1,2,4-triazol-1-yl)propyl]benzamide.
Claim 17
Dependent Claim
27 words
A method of inhibiting thromboxane synthetase enzyme in a mammal which comprises administering to said mammal an effective amount of a compound as recited in claim 1.
Claim 18
Dependent Claim
36 words
A thromboxane synthetase enzyme inhibiting composition of matter in dosage unit form comprising from about 10 mg to about 700 mg of a compound as recited in claim 1 in association with a pharmaceutically acceptable carrier.
Claim 19
Dependent Claim
25 words
A method of inhibiting hypertension in a mammal which comprises administering to said mammal an effective amount of a compound as recited in claim 1.
References Cited (Backward Citations)
US4320134A
Cited
DE2854598A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-02-03 | 1989-08-05 | 1990-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-02-03 | 1993-08-05 | 1994-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-02-03 | 1997-08-05 | 1998-02-04 | $7700.00 | Window Closed / Lapsed |